These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 9500493)
21. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995 [TBL] [Abstract][Full Text] [Related]
22. [Effects of Dioscorea septemloba on bone metabolism in ovariectomized rats]. Xing GS; Lou JS; Wang ZB; Yu SL; Wang Y; Sheng L Zhongguo Zhong Yao Za Zhi; 2007 Sep; 32(18):1909-13. PubMed ID: 18051905 [TBL] [Abstract][Full Text] [Related]
23. Treatment with QiBaoMeiRan, a Chinese herbal formula, prevents bone loss in ovariectomized rat. Xu Y; Ma X; An J; Ding J; Dai G; Liu Z; Song Z; Lin N Climacteric; 2016; 19(1):98-106. PubMed ID: 26514578 [TBL] [Abstract][Full Text] [Related]
24. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. Chavassieux P; Garnero P; Duboeuf F; Vergnaud P; Brunner-Ferber F; Delmas PD; Meunier PJ J Bone Miner Res; 2001 Jan; 16(1):89-96. PubMed ID: 11149494 [TBL] [Abstract][Full Text] [Related]
25. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. El-Shitany NA; Hegazy S; El-Desoky K Phytomedicine; 2010 Feb; 17(2):116-25. PubMed ID: 19577454 [TBL] [Abstract][Full Text] [Related]
26. Bone remodeling and bone mineral density during pregnancy. Ulrich U; Miller PB; Eyre DR; Chesnut CH; Schlebusch H; Soules MR Arch Gynecol Obstet; 2003 Oct; 268(4):309-16. PubMed ID: 14504876 [TBL] [Abstract][Full Text] [Related]
27. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473 [TBL] [Abstract][Full Text] [Related]
28. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ; J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495 [TBL] [Abstract][Full Text] [Related]
29. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373 [TBL] [Abstract][Full Text] [Related]
30. Phytoestrogenic effects of black tea extract (Camellia sinensis) in an oophorectomized rat (Rattus norvegicus) model of osteoporosis. Das AS; Das D; Mukherjee M; Mukherjee S; Mitra C Life Sci; 2005 Oct; 77(24):3049-57. PubMed ID: 15996685 [TBL] [Abstract][Full Text] [Related]
31. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. Marie PJ; Hott M; Modrowski D; De Pollak C; Guillemain J; Deloffre P; Tsouderos Y J Bone Miner Res; 1993 May; 8(5):607-15. PubMed ID: 8511988 [TBL] [Abstract][Full Text] [Related]
32. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue. Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149 [TBL] [Abstract][Full Text] [Related]
33. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Genazzani AR; Bernardi F; Stomati M; Monteleone P; Luisi S; Rubino S; Farzati A; Casarosa E; Luisi M; Petraglia F Neuroendocrinology; 2000 Sep; 72(3):162-70. PubMed ID: 11025410 [TBL] [Abstract][Full Text] [Related]
34. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW Menopause; 2003; 10(4):337-44. PubMed ID: 12851517 [TBL] [Abstract][Full Text] [Related]
35. The effects of strength training and raloxifene on bone health in aging ovariectomized rats. Stringhetta-Garcia CT; Singulani MP; Santos LF; Louzada MJ; Nakamune AC; Chaves-Neto AH; Rossi AC; Ervolino E; Dornelles RC Bone; 2016 Apr; 85():45-54. PubMed ID: 26812611 [TBL] [Abstract][Full Text] [Related]
36. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. Erlandsson MC; Jonsson CA; Lindberg MK; Ohlsson C; Carlsten H J Endocrinol; 2002 Nov; 175(2):319-27. PubMed ID: 12429030 [TBL] [Abstract][Full Text] [Related]
37. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. Botella S; Restituto P; Monreal I; Colina I; Calleja A; Varo N J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743 [TBL] [Abstract][Full Text] [Related]
38. Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Kim MH; Bae YJ; Choi MK; Chung YS Biol Trace Elem Res; 2009 Jun; 128(3):239-47. PubMed ID: 19034393 [TBL] [Abstract][Full Text] [Related]
39. Correlation between salivary and serum markers of bone turnover in osteopenic rats. Pellegrini GG; Gonzales CM; Somoza JC; Friedman SM; Zeni SN J Periodontol; 2008 Jan; 79(1):158-65. PubMed ID: 18166106 [TBL] [Abstract][Full Text] [Related]
40. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. Greenspan SL; Resnick NM; Parker RA J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]